MINNEAPOLIS (March 27, 2017) – Pharmacogenomics company OneOme today announced the results of its clinician pharmacogenomic testing awareness survey. OneOme will formally share its findings at the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, which begins March 27 in Denver. OneOme’s poster, Strategies for increasing clinician awareness of pharmacogenomic testing, will be presented on March 28, 2017 from 5:45-7:30 p.m.
The study, conducted by researchers from OneOme, surveyed clinicians to determine their awareness of pharmacogenomic (PGx) testing and whether clinicians can easily interpret and share results with their patients. Results showed that while barriers such as resources and awareness still exist, the use of clinical decision support tools such as the RightMed® PGx clinical test report and RightMed Advisor can mitigate these concerns and ensure pharmacogenomics is implemented effectively and safely.
“OneOme’s RightMed test has tremendous potential to improve health and lower the overall cost of care – and we are committed to making this technology accessible to healthcare providers,” said Paul Owen, CEO of OneOme. “It was encouraging to see that we can lower the barriers for implementing pharmacogenomics using our approach of translating complex scientific information into an easily understood and clinically actionable format. There is a lot of progress still needed to help clinicians understand the power of pharmacogenomic testing and how to integrate it into their practice – and not allow it to become another test taken and forgotten by the provider. We are committed to spearheading this effort with our clients. Together, we can create a more personal, effective and safe patient care experience.”
More than four billion prescriptions are issued each year in the U.S., however, not all drugs are effective for all people. In fact, response rates for many drugs are only between 50-75 percent. Adverse drug reactions are now the fourth-leading cause of death. OneOme’s RightMed test, which was co-developed and exclusively licensed from Mayo Clinic, makes prescriptions personal by using a patient’s genetic information to better predict their response to medication.
The RightMed test was developed to offer a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22+ genes provided as part of routine clinical care. By ordering and reviewing the results of the test, physicians will have a better idea of how their patients’ certain genes will respond to more than 340 medications.
OneOme has also developed a platform for clients to generate the interpretative drug report using genotype or sequence data obtained elsewhere, all with the goal of better identifying which prescription medications may work best for individual patients. To ensure that healthcare providers can easily order the RightMed test and access results throughout a patient’s lifetime, OneOme is integrating results into a patient’s electronic medical records (EMR).
Anyone can take the RightMed test, although some patients who may benefit most include: those who are taking some classes of medication, such as cardiovascular or psychiatric patients; those who are struggling with adverse drug reactions or medications that are not working; or those who are on multiple medications.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.